Planned AIDS vaccine trial raises concerns

The AIDS Vaccine Research Subcommittee of the NIH has OK'd a new AIDS vaccine trial, prompting some skeptics to caution against plunging back into trials so soon after a Merck program misfired.

"We're redesigning the aims of human HIV vaccine research without redesigning the vaccine," said Scripps Research Institute immunologist Dennis Burton. "Let's not go into a human experiment without a clear idea of what we're going to learn."

Emory University's Eric Hunter, though, said the new vaccine was sufficiently different from Merck's to warrant a study. The vaccine is based on the adenovirus type 5 and given after a schedule of three DNA-based immunizations aimed at priming the human immune system. Merck's vaccine was administered without the DNA priming.

- read the article from The Scientist

ALSO: Researchers at Mymetics insists that a new HIV vaccine can be successful by building on the experiences of the past 20 years. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.